In 2020, ATNAHS added Zestril (lisinopril) and Zestoretic (lisinopril and hydrochlorothiazide) to their portfolio of heritage brands

In 2020, ATNAHS acquired the global commercial rights from AstraZeneca to a number of hypertension medicines including Zestril (lisinopril) and Zestoretic (lisinopril and hydrochlorothiazide).

Zestril is indicated for hypertension, heart failure, acute myocardial infarction, and renal complications of diabetes mellitus.¹ Zestoretic is indicated in the management of mild to moderate hypertension in patients who have been stabilised on its individual components given in the same proportions.²

History and development of Zestril (lisinopril) and Zestoretic (lisinopril and hydrochlorothiazide)

The Zestril molecule lisinopril is a synthetic peptide derivative of captopril, which itself was derived from the venom of a Brazilian pit viper.^4,5

Zestril is an angiotensin-converting enzyme (ACE) inhibitor, whilst Zestoretic is a combination of this ACE-inhibitor and a diuretic.

The discovery of ACE-inhibitors is considered to be one of the great advances in cardiovascular medicine.⁴

Prinivil (the brand name of lisinopril in the US), was patented in 1978 and approved for medical use for hypertension in the US in 1987.5 The rights to lisinopril were subsequently licensed to Zeneca to co-market the drug using the brand name Zestril. Zestoretic, also from Zeneca, was approved for medical use in the US in 1989.⁶

Our commitment in hypertension continues

Zestril is licensed to treat hypertension, congestive heart failure, diabetic-related conditions and hypertensive renal disease. Zestril may also help improve survival after a heart attack.¹

Zestoretic is a combination of the Zestril ACE inhibitor and a diuretic used to treat hypertension.²

With Zestril and Zestoretic, ATNAHS will continue to offer cardiovascular solutions that patients, healthcare systems and regulators value.

A brand with a valuable heritage

Over $1.0 billion sales in 1997⁷

By 1997, Zestril was Zeneca’s largest selling product worldwide⁹ and retained its blockbuster status in the years following.⁸

A molecule with an extensive patient heritage

98 million prescriptions in the US in 2018⁸

The Zestril molecule (lisinopril) was the No.1 prescribed drug in the USA 5 out of 6 years between 2012 to 2017 and was prescribed 98 million times during 2018.⁸

Disclaimer

All of the information presented above is factual historical information that is available in the public domain and is included in good faith. It is not the intention to make any new or fresh claims nor to be promotional for the product in question.

References

Zestril 5mg tablets, Summary of Product Characteristics.
Zestoretic 20, Summary of Product Characteristics.
Pharmaceutical Technology. 2 March 2020. Available from https://www.pharmaceutical-technology.com/news/astrazeneca-hypertension-drugs-atnahs-pharma/ [Last accessed January 2021].
Patchett AA et al. A new class of angiotensin-converting enzyme inhibitors. Nature. 1980 Nov 20;288(5788):280–3. Available from https://www.nature.com/articles/288280a0 [Last accessed January 2021].
Bryan J. From snake venom to ACE inhibitor — the discovery and rise of captopril. Pharmaceutical J. 17 April 2009. Available from https://www.pharmaceutical-journal.com/news-and-analysis/from-snake-venom-to-ace-inhibitor-the-discovery-and-rise-of-captopril/10884359.article [Last accessed January 2021].
Drugs.com. Available from https://www.drugs.com/availability/generic-zestoretic.html [Last accessed January 2021].
The Pharma Letter, 2 December 1998. Available from https://www.thepharmaletter.com/article/zeneca-s-zestril-most-prescribed-ace- inhibitor-in-usa [Last accessed January 2021].
ClinCalc.com. Available from https://clincalc.com/DrugStats/Drugs/Lisinopril [Last accessed January 2021].

For further Zestril^® product information please follow this link to the relevant product page on this site.

For further Zestoretic^® product information please follow this link to the relevant product page on this site.